Advarra, a provider of institutional review board (IRB), institutional biosafety committee (IBC), research technology solutions, and quality and compliance consulting services, has acquired IRB Company, Inc., an AAHRPP-accredited central IRB that conducts research reviews in the U.S.  

Advarra products and services aim to streamline processes, create efficiencies, and support research compliance. Advarra continues to expand, serving more than 3,200 research institutions, hospital systems, and academic medical centers.

"Advarra builds on its commitment to advance human health and better enable clinical trials with this acquisition," said Gadi Saarony, CEO of Advarra. "IRBco studies will be fully integrated with Advarra in a matter of weeks, and we look forward to the additional talent and board expertise this will bring to our organization. We will maintain our focus on developing altogether better capabilities that serve clients and protect research participants."

"Joining the Advarra family is an ideal fit," said Dr. Anil Sharma, CEO of IRBco. "We are pleased to offer our mutual customers expanded resources—innovations, efficiencies, and all the characteristics to collaboratively complement moving research forward."

The broader suite of Advarra technology products and consulting services aim to reduce operational costs, streamline study startup activities, prevents errors and administrative burdens for clinical research sponsors, CROs, investigators, and institutions.
 

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.